Immune checkpoint inhibitors (ICI), especially anti-programmed cell death-1 (PD-1) antibodies, as effective immunotherapeutic agents, effectively improve the survival of HCC [4]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.